---
layout: default
title: Dopamine Hcl
parent: 僅模型預測 (L5)
nav_order: 183
evidence_level: L5
indication_count: 0
---

# Dopamine Hcl
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

The data-report skill's fidelity principle applies here: I must report only what the Evidence Pack actually contains, with no fabrication. The pack has significant gaps — particularly an empty `predicted_indications` array — so sections that cannot be populated are omitted entirely per the format rules.

---

# Dopamine HCl: Evidence Pack Incomplete — No Repurposing Predictions Available

## One-Sentence Summary

Dopamine HCl is a catecholamine medicine used in the acute management of haemodynamic instability and shock states.
The current Evidence Pack contains **no TxGNN repurposing predictions** for this drug, and critical data — including mechanism of action, approved indications, and safety warnings — are absent.
This report summarises what is available and identifies the actions required before a repurposing analysis can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current Evidence Pack |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | Not applicable — no predictions available |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | **Hold** |

---

## South Africa Market Information

No SAHPRA product registrations were found for Dopamine HCl. The drug is recorded as **not marketed** under this name.

> Dopamine HCl is widely used as a critical care medicine in South African hospitals, typically as an imported or unlicensed hospital product. Confirm current availability and approved status through the National Department of Health Essential Medicines Programme or hospital pharmacy channels.

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN repurposing predictions have been generated for Dopamine HCl, and the Evidence Pack is missing the core drug-level data required for any mechanistic or clinical analysis. Proceeding without this foundation would produce an unreliable assessment.

**To proceed, the following is needed:**

- **Resolve DG001** — Obtain the package insert (PI) from SAHPRA or an equivalent recognised source to extract approved indications, key warnings, and contraindications
- **Resolve DG002** — A DrugBank query run on 2026-03-26 returned 1 result; extract and confirm the DrugBank ID and mechanism of action from that record before re-querying
- **Re-run TxGNN pipeline** — Once the DrugBank ID is confirmed, re-submit to the TxGNN prediction pipeline to generate repurposing candidates
- **Clarify SAHPRA status** — If no formal product registration exists, determine whether Dopamine HCl is available as a scheduled substance or hospital medicine under South African pharmacy regulations, and note the applicable Essential Medicines List (EML) category if relevant
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

